Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571026 | 1.00 | RAB9A (0.58) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL25911640 | 0.85 | ALDH1A1 (0.46) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL16906037 | 0.84 | GRM4 (0.48) | RAB9AKMT2AALDH1A1PKMMAPT | |
| SCHEMBL31203256 | 0.83 | KMT2A (0.46) | RAB9AKMT2AALDH1A1NPC1MAPT | |
| SCHEMBL27030120 | 0.82 | ALDH1A1 (0.48) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL30355109 | 0.82 | ALDH1A1 (0.48) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL2321687 | 0.81 | RAB9A (0.53) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL3973119 | 0.81 | RAB9A (0.53) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL3973117 | 0.81 | RAB9A (0.53) | RAB9AKMT2AALDH1A1PKMNPC1 | |
| SCHEMBL15708023 | 0.80 | NMT1 (0.58) | ALDH1A1MAPTSMN1; SMN2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728007-B2 | Therapeutic amides | WAYNE STATE UNIVERSITY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7585863-B2 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | WAYNE STATE UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| US-7507749-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090076073-A1 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY | 2009-03-19 | — | — | US | disclosed |
| US-20070232643-A1 | Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides | WAYNE STATE UNIVERSITY | 2007-10-04 | — | — | US | disclosed |
| US-7241894-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060293333-A1 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | WAYNE STATE UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-7109341-B2 | Therapeutic amides | WAYNE STATE UNIVERSITY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050159447-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| EP-1539699-A1 | 4- 7'-HALO-2-QUINO (XA-) LINYLOXY!PHENOXY-PROPIONIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS | WAYNE STATE UNIVERSITY (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6867219-B2 | Antitumor agents | WAYNE STATE UNIVERSITY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1412332-B1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | UNIV WAYNE STATE (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040132618-A1 | Therapeutic amides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2004-07-08 | — | — | US | disclosed |
| EP-1412332-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004005260-A1 | A-`7-HALO-2-QUINO (XA-) LINYLOXY!PHENOXY-PROPIONIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS | WAYNE STATE UNIVERSITY (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004004651-A2 | THERAPEUTIC AMIDES | WAYNE STATE UNIVERSITY (US) | 2004-01-15 | — | — | WO | disclosed |
| US-20030144321-A1 | Antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| WO-2003011832-A1 | QUINOLINE DERIVATIVES AND USE THEREOF AS ANTITUMOR AGENTS | WAYNE STATE UNIVERSITY (US) | 2003-02-13 | — | — | WO | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293333-A1 | Antitumor agents; such as (2-(4-(7-Chloro-2-quinoxalinyl)oxy)propionylamino ethansulfonic acid; {2-{4-(7-Chloro-quinoxalin-2-yloxy)-phenoxy}propionyl amino}acetic acid | ANXA5, TP53, PRDX6 | RAB9A 1249/4885KMT2A 1709/4885ALDH1A1 329/4885 |
| US-20070232643-A1 | Quinoline derivative, e.g. 2[4-(7-chloroquinolin-2-yloxy)phenoxy]propionic acid sodium salt; anticarcinogenic, antitumor agent; colon, breast, melanoma, pancreatic cancer or adenocarcinoma; melanoma, or leukemia; based on herbicides | NRAS, KRAS, BRAF | RAB9A 2030/4885KMT2A 69/4885ALDH1A1 383/4885 |
| US-20040132618-A1 | Therapeutic amides | HDAC5, HDAC6, ASAH2 | RAB9A 650/4885KMT2A 521/4885ALDH1A1 1175/4885 |
| US-20030144321-A1 | Antitumor agents | MCL1, FLI1, MGMT | RAB9A 1504/4885KMT2A 405/4885ALDH1A1 856/4885 |
| US-20050159447-A1 | Antitumor agents | MGMT, TP53, MCL1 | RAB9A 1438/4885KMT2A 298/4885ALDH1A1 1237/4885 |
| US-20090076073-A1 | THERAPEUTIC AMIDES | HDAC5, HDAC6, ASAH2 | RAB9A 502/4885KMT2A 477/4885ALDH1A1 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.